Detalhe da pesquisa
1.
Efficacy, safety, and tolerability of nivasorexant in adults with binge-eating disorder: A randomized, Phase II proof of concept trial.
Int J Eat Disord
; 56(11): 2120-2130, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584285
2.
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.
Ann Neurol
; 87(3): 347-356, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31953863
3.
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.
Cancer
; 121(13): 2185-92, 2015 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25809731
4.
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
Lancet Neurol
; 21(2): 125-139, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35065036
5.
Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
Drugs Aging
; 39(10): 795-810, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36098936
6.
Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder.
Neurology
; 94(21): e2222-e2232, 2020 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32341187
7.
Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells.
Stem Cells Dev
; 17(6): 1095-107, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19006451
8.
Customised birthweight: coefficients for an Australian population and validation of the model.
Aust N Z J Obstet Gynaecol
; 46(5): 388-94, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16953852